Neoseptin-3 | CAS#1622863-21-1

MedKoo Cat#: 525442 | Name: Neoseptin-3

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Neoseptin-3 is a novel specific agonist of the mouse TLR4 (mTLR4)/myeloid differentiation factor 2 (MD-2) complex.

Chemical Structure

Neoseptin-3

CAS#1622863-21-1

Theoretical Analysis

MedKoo Cat#: 525442

Name: Neoseptin-3

CAS#: 1622863-21-1

Chemical Formula: C29H34N2O4

Exact Mass: 474.2519

Molecular Weight: 474.60

Elemental Analysis: C, 73.39; H, 7.22; N, 5.90; O, 13.48

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 240.00
25mg	USD 610.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Neoseptin-3

IUPAC/Chemical Name

(alphaS)-alpha-[[4-Amino-3-[2-(4-hydroxyphenyl)ethyl]benzoyl]amino]-benzenebutanoic acid tert-butyl ester

InChi Key

OACODUCFPHHCIH-SANMLTNESA-N

InChi Code

InChI=1S/C29H34N2O4/c1-29(2,3)35-28(34)26(18-12-20-7-5-4-6-8-20)31-27(33)23-14-17-25(30)22(19-23)13-9-21-10-15-24(32)16-11-21/h4-8,10-11,14-17,19,26,32H,9,12-13,18,30H2,1-3H3,(H,31,33)/t26-/m0/s1

SMILES Code

O=C(OC(C)(C)C)[C@@H](NC(C1=CC=C(N)C(CCC2=CC=C(O)C=C2)=C1)=O)CCC3=CC=CC=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Neoseptin 3 is a Toll-like receptor 4/myeloid differentiation factor 2 (mTLR4/MD-2) agonist with an EC50 of 18.5 μM.

In vitro activity:

Neoseptin-3 activates mTLR4/MD-2 independently of CD14 and triggers canonical myeloid differentiation primary response gene 88 (MyD88)- and Toll-interleukin 1 receptor (TIR) domain-containing adaptor inducing IFN-beta (TRIF)-dependent signaling. The crystal structure mTLR4/MD-2/Neoseptin-3 at 2.57-Å resolution reveals that Neoseptin-3 binds as an asymmetrical dimer within the hydrophobic pocket of MD-2, inducing an active receptor complex similar to that induced by lipid A. Reference: Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E884-93. https://pubmed.ncbi.nlm.nih.gov/26831104/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	210.70

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 474.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

Wang Y, Su L, Morin MD, Jones BT, Whitby LR, Surakattula MM, Huang H, Shi H, Choi JH, Wang KW, Moresco EM, Berger M, Zhan X, Zhang H, Boger DL, Beutler B. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E884-93. doi: 10.1073/pnas.1525639113. Epub 2016 Feb 1. Erratum in: Proc Natl Acad Sci U S A. 2016 Apr 5;113(14 ):E2096. Erratum in: Proc Natl Acad Sci U S A. 2021 Jun 15;118(24): PMID: 26831104; PMCID: PMC4763747.

In vitro protocol:

In vivo protocol:

TBD

1: Wang Y, Su L, Morin MD, Jones BT, Whitby LR, Surakattula MM, Huang H, Shi H, Choi JH, Wang KW, Moresco EM, Berger M, Zhan X, Zhang H, Boger DL, Beutler B. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E884-93. doi: 10.1073/pnas.1525639113. Epub 2016 Feb 1. Erratum in: Proc Natl Acad Sci U S A. 2016 Apr 5;113(14 ):E2096. PubMed PMID: 26831104; PubMed Central PMCID: PMC4763747.